Refine by
Cardiovascular Research Articles & Analysis
34 news found
Cardiovascular disease models are essential tools used in the research of heart-related conditions. ...
The incidence of landscape fires has been rising globally, leading to increased exposure to landscape fire smoke (LFS) among millions of people. The inhalation of particulate matter (PM) from LFS is associated with adverse respiratory and cardiovascular outcomes. However, the mechanisms by which LFS impacts these functions remain inadequately understood. This blog focuses on a new ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the Journal of Cardiovascular Translational Research that examined pressure-volume profiles in heart failure patients using Daxor’s BVA-100 blood test to measure intravascular volume overload compared to a commercially available ...
Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clinical safety data from the Phase 1 dose escalation Phase 2 clinical data readouts on safety and efficacy of XC001 anticipated in 2022 Company plans to commence study startup of XC001 as an adjunct to CABG in 2H21, and clinical studies in additional ...
Osso VR, now the largest and fastest-growing virtual reality (VR) company in healthcare, and the American College of Cardiology (ACC), a global nonprofit dedicated to transforming cardiovascular care, today announced a new collaboration to develop an immersive, VR-enabled training program for cardiovascular professionals. ...
The image acquisition was led by Edris Aman M.D. while the procedure was performed and HTG guidance utilized by Gagan Singh, M.D., director, Cardiovascular Research Unit. MitraClip is a procedure that approximates the mitral valve leaflets thereby addressing an incompetent valve that is regurgitating, also known as ...
“The AHA Scientific Sessions is a leading event connecting over 15,000 experts from over one hundred countries focused on cardiovascular research and clinical practice. BVA guided treatment in heart failure has shown to reduce heart failure 30-day readmissions by 56%, 30-day mortality by 82%, 1-year mortality by 86% and when done on admission, lowers ...
(NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, has initiated the first-ever prospective coronary intervention study consisting of all female patients – EMPOWER CAD – to determine whether the positive results from earlier coronary IVL studies with the Shockwave C2 Coronary IVL ...
The Cardiovascular Research Foundation (CRF) is pleased to announce that Puzzle Medical Devices Inc. has won the TCT 2022 Shark Tank Innovation Competition for its novel circulatory support device that is implanted percutaneously in the abdominal aorta. The competition took place during Transcatheter Cardiovascular Therapeutics (TCT), the ...
The striking fact drives a great deal of cardiovascular research worldwide, among which peptide development is brought into focus owing to its certain effects on the remission and prevention of diseases. BOC Sciences provides an extensive list of peptides for research on diabetes, cancers, HIV, etc. Its peptides for ...
Since 1980 he was a Director of the Clinical Research Program of the Catheterization Laboratory, Thorax Center at Erasmus University, and till April 1st 2014 (retirement date) the Head of the Interventional Department, Thorax Center, Erasmus MC (University Medical Center Rotterdam), Rotterdam, The Netherlands. Since April 2013 he holds the position of Professor of Cardiology in ...
Positive Phase 1 results reported at the American Association for Thoracic Surgery (AATS) and the American Society of Gene and Cell Therapy (ASGCT) revealed XC001 is well tolerated at all dose levels Phase I data support XC001 therapeutic effect and potential dose response Topline Phase 2 data readout expected in February 2023 with interim results in the second half of this year XyloCor ...
(NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today new data confirming excellent one-year outcomes with coronary IVL in both women and men. ...
PT Location: Room 009, Moscone Center vMap Clinical Validation Study Design The vMap Clinical Validation Study was a blinded, multicenter evaluation with final data analysis performed by an independent core laboratory, the Cardiovascular Research Foundation (New York, NY). A total of 255 episodes from 225 patients from four study centers, including Medical ...
In the Phase 1 portion of the EXACT study, 12 subjects with Canadian Cardiovascular Society (CCS) angina class 2-4 without revascularization options were divided into four escalating dose groups with three subjects each. ...
Outcomes from a previous Lungpacer clinical study published in theFebruary 2022 edition of the American Journal of Respiratory Critical Care Medicine showed Lungpacer therapy strengthened the diaphragm 246% more, and improved lung function 128% more than patients who did not receive the therapy.[1] The growing body of research including more than 44 scientific presentations and ...
Jean-Claude Tardif, director of MHI's Research Center, professor of medicine at Université de Montréal, and holder of the Canada Research Chair in personalized medicine. ...
ByBIOMODEX
The publication is based on 20 years of both basic and clinical research, performed primarily at Tulane University (New Orleans, LA, USA), MD Anderson Cancer Center-University of Texas (Houston, TX, USA), Methodist Research Center (Houston, TX, USA), Sanford Health University of South Dakota (Sioux Falls, SD, USA), and at Isar Klinikum (Munich, Germany). Tulane ...
Javed Butler, the Patrick H. Lehan Chair in Cardiovascular Research, and professor and chairman of the department of medicine at the University of Mississippi Medical Center. ...
ByBayer AG
Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company focused on developing transformative therapeutic products for large unmet clinical needs in procedure-based medicine, today announced multiple presentations of long-term clinical results and ISH subgroup data from the MODERATO II study of BackBeat Cardiac Neuromodulation ...